Eupraxia Pharmaceuticals (EPRX) News Today $5.35 -0.24 (-4.31%) Closing price 07/15/2025 03:55 PM EasternExtended Trading$5.69 +0.34 (+6.36%) As of 07/15/2025 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EPRX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Eupraxia Pharmaceuticals (EPRX) Receives a Buy from Raymond JamesJuly 11, 2025 | theglobeandmail.comEupraxia Pharma Shares Climb on Dosing of First EP-104GI Study PatientJuly 8, 2025 | marketwatch.comEupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic EsophagitisJuly 8, 2025 | globenewswire.comQ2 Earnings Estimate for EPRX Issued By HC WainwrightJune 30, 2025 | marketbeat.comEupraxia Pharmaceuticals Stock Short Interest Report | NASDAQ:EPRX - BenzingaJune 27, 2025 | benzinga.comEupraxia Pharmaceuticals (NASDAQ:EPRX) Upgraded by HC Wainwright to "Strong-Buy" RatingJune 27, 2025 | marketbeat.comEupraxia Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:EPRX - BenzingaJune 26, 2025 | benzinga.comEupraxia Pharma director buys as stock tests top of rangeJune 26, 2025 | theglobeandmail.comHC Wainwright & Co. Initiates Coverage of Eupraxia Pharmaceuticals (EPRX) with Buy RecommendationJune 26, 2025 | msn.comThis NRG Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For ThursdayJune 26, 2025 | benzinga.comEupraxia Pharmaceuticals (NASDAQ:EPRX) Now Covered by Analysts at Canaccord Genuity GroupJune 16, 2025 | marketbeat.comEupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Price Down 0.8% - Should You Sell?June 6, 2025 | marketbeat.comEupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Short Interest UpdateJune 5, 2025 | marketbeat.comEupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of ShareholdersJune 2, 2025 | globenewswire.comEupraxia Pharmaceuticals (EPRX) Expected to Announce Quarterly Earnings on WednesdayMay 9, 2025 | marketbeat.comEupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025May 7, 2025 | financialpost.comFEupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025May 7, 2025 | globenewswire.comEupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial ResultsMay 7, 2025 | finanznachrichten.deEupraxia Pharmaceuticals Reports First Quarter 2025 Financial ResultsMay 6, 2025 | globenewswire.comEupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and MayApril 24, 2025 | financialpost.comFEupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and MayApril 24, 2025 | financialpost.comFEupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and MayApril 24, 2025 | globenewswire.comEupraxia Pharmaceuticals IncApril 8, 2025 | uk.investing.comEupraxia Pharmaceuticals (EPRX) Projected to Post Earnings on MondayMarch 31, 2025 | marketbeat.comRaymond James Sticks to Their Buy Rating for Eupraxia Pharmaceuticals (EPRX)March 25, 2025 | markets.businessinsider.comHere's Why We're Watching Eupraxia Pharmaceuticals' (TSE:EPRX) Cash Burn SituationMarch 22, 2025 | finance.yahoo.comEupraxia Pharmaceuticals (NASDAQ:EPRX) Announces Earnings ResultsMarch 21, 2025 | marketbeat.comEupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial ResultsMarch 21, 2025 | finanznachrichten.deEupraxia Pharmaceuticals reports FY24 EPS (76c), consensus (63c)March 21, 2025 | markets.businessinsider.comEupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial ResultsMarch 20, 2025 | prnewswire.comEupraxia Pharmaceuticals (NASDAQ:EPRX) Trading Down 1.7% - What's Next?March 18, 2025 | marketbeat.comEupraxia Pharmaceuticals management to meet virtually with Craig-HallumMarch 4, 2025 | markets.businessinsider.comEupraxia Pharmaceuticals’ EP-104GI shows efficacy in esophagitis trialFebruary 25, 2025 | markets.businessinsider.comEupraxia Pharmaceuticals (EPRX) Receives a Buy from Craig-HallumFebruary 25, 2025 | markets.businessinsider.comEupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisFebruary 25, 2025 | prnewswire.comCraig Hallum Initiates Coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX)February 22, 2025 | marketbeat.comEupraxia Pharmaceuticals Taps Alex Rothwell as CFOFebruary 18, 2025 | marketwatch.comEupraxia Pharmaceuticals Announces CFO SuccessionFebruary 18, 2025 | prnewswire.comEupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Short Interest Down 6.0% in JanuaryFebruary 18, 2025 | marketbeat.comEupraxia Pharmaceuticals (NASDAQ:EPRX) Trading Up 1.9% - Should You Buy?February 14, 2025 | marketbeat.comEupraxia Pharmaceuticals (NASDAQ:EPRX) Shares Down 3.5% - Here's What HappenedJanuary 23, 2025 | marketbeat.comEupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Short Interest Up 6.0% in DecemberJanuary 1, 2025 | marketbeat.comEupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Price Down 1% - Should You Sell?December 25, 2024 | marketbeat.comEupraxia Pharmaceuticals Unveils Promising Drug Delivery DataNovember 21, 2024 | markets.businessinsider.comEupraxia presents new PK data from its Phase 2a Eosinophilic Esophagitis programNovember 20, 2024 | markets.businessinsider.comEupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six MonthsNovember 20, 2024 | prnewswire.comEupraxia Pharmaceuticals reports regulatory updateNovember 15, 2024 | uk.investing.comEupraxia Pharmaceuticals Showcases Innovation at ACR 2024November 15, 2024 | markets.businessinsider.comEupraxia Pharmaceuticals (NASDAQ:EPRX) Rating Increased to Strong-Buy at RODMAN&RENSHAWNovember 15, 2024 | marketbeat.comEupraxia Pharmaceuticals initiated with a Buy at Rodman & RenshawNovember 14, 2024 | markets.businessinsider.com Get Eupraxia Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address EPRX Media Mentions By Week EPRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EPRX News Sentiment▼0.620.97▲Average Medical News Sentiment EPRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EPRX Articles This Week▼21▲EPRX Articles Average Week Get Eupraxia Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CorMedix News Today Immunome News Today Syndax Pharmaceuticals News Today KalVista Pharmaceuticals News Today Replimune Group News Today Xeris Biopharma News Today Vir Biotechnology News Today Gyre Therapeutics News Today Nuvation Bio News Today Sana Biotechnology News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EPRX) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eupraxia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eupraxia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EPRX Stock Alerts